INSIDER · CIK 1727334
Robinson Chandler
Chief Executive Officer, Director at Monopar Therapeutics (MNPR)
↗5 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$2.6MSold on the market
1Companies
Oct 20, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 202616:59 | Oct 20, 2026 | MNPRMonopar Therapeutics | Chief Executive Officer, Director | F · Tax | $92.59 | −597 | 104,127 | -1% | $55K | ||
| Oct 2, 202618:14 | Sep 30, 2026 | MNPRMonopar Therapeutics | Chief Executive Officer, Director | M · Exercise | — | +9,801 | 109,068 | +10% | — | ||
| Oct 2, 202618:14 | Sep 30, 2026 | MNPRMonopar Therapeutics | Chief Executive Officer, Director | F · Tax | $79.67 | −4,344 | 104,724 | -4% | $346K | ||
| Sep 28, 202620:47 | Sep 24, 2026 | MNPRMonopar Therapeutics | Chief Executive Officer, Director | S · Sell10b5-1 | $88.00 | −29,056 | 99,267 | -23% | −$2.6M | ||
| Sep 28, 202620:47 | Sep 24, 2026 | MNPRMonopar Therapeutics | Chief Executive Officer, Director | M · Exercise10b5-1 | $21.74 | +29,056 | 128,323 | +29% | $632K |